{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T20:52:16Z","timestamp":1795035136754,"version":"4.10.2"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug and Alcohol Dependence"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.drugalcdep.2020.108221","type":"journal-article","created":{"date-parts":[[2020,8,4]],"date-time":"2020-08-04T21:49:26Z","timestamp":1596577766000},"page":"108221","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Health-related quality of life and opioid use disorder pharmacotherapy: A secondary analysis of a clinical trial"],"prefix":"10.1016","volume":"215","author":[{"given":"Ali","family":"Jalali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle A.","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip J.","family":"Jeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn E.","family":"McCollister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jared A.","family":"Leff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua D.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward V.","family":"Nunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Novo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Rotrosen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce R.","family":"Schackman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean M.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drugalcdep.2020.108221_bib0005","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jsat.2017.01.019","article-title":"Quality of life as an outcome of opioid use disorder treatment: a systematic review","volume":"76","author":"Bray","year":"2017","journal-title":"J. Subst. Abuse Treat."},{"issue":"2","key":"10.1016\/j.drugalcdep.2020.108221_bib0010","doi-asserted-by":"crossref","first-page":"317","DOI":"10.3368\/jhr.50.2.317","article-title":"A practitioner\u2019s guide to cluster-robust inference","volume":"50","author":"Cameron","year":"2015","journal-title":"J. Hum. Resour."},{"issue":"5","key":"10.1016\/j.drugalcdep.2020.108221_bib0015","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.drugpo.2010.01.010","article-title":"Quality of life among opiate-dependent individuals: a review of the literature","volume":"21","author":"De Maeyer","year":"2010","journal-title":"Int. J. Drug Policy"},{"issue":"4","key":"10.1016\/j.drugalcdep.2020.108221_bib0020","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.drugpo.2012.09.005","article-title":"Profiles of quality of life in opiate-dependent individuals after starting methadone treatment: a latent class analysis","volume":"24","author":"De Maeyer","year":"2013","journal-title":"Int. J. Drug Policy"},{"issue":"11","key":"10.1016\/j.drugalcdep.2020.108221_bib0025","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1097\/00005650-199711000-00002","article-title":"Modeling valuations for EuroQol health states","volume":"35","author":"Dolan","year":"1997","journal-title":"Med. Care"},{"issue":"12","key":"10.1016\/j.drugalcdep.2020.108221_bib0030","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1016\/j.joca.2015.07.005","article-title":"Latent Class Growth Analysis predicts long term pain and function trajectories in total knee arthroplasty: a study of 689 patients","volume":"23","author":"Dowsey","year":"2015","journal-title":"Osteoarthr. Cartil."},{"key":"10.1016\/j.drugalcdep.2020.108221_bib0035","series-title":"Methods for the Economic Evaluation of Health Care Programmes","author":"Drummond","year":"2015"},{"key":"10.1016\/j.drugalcdep.2020.108221_bib0040","series-title":"EQ-5D","author":"EuroQol","year":"2017"},{"key":"10.1016\/j.drugalcdep.2020.108221_bib0045","series-title":"Economic Evaluation in Clinical Trials","author":"Glick","year":"2015"},{"issue":"3","key":"10.1016\/j.drugalcdep.2020.108221_bib0050","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.drugalcdep.2010.02.020","article-title":"Patterns of drug use and abuse among aging adults with and without HIV: a latent class analysis of a US Veteran cohort","volume":"110","author":"Green","year":"2010","journal-title":"Drug Alcohol Depend."},{"issue":"3","key":"10.1016\/j.drugalcdep.2020.108221_bib0055","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","article-title":"EuroQol - a new facility for the measurement of health-related quality of life","volume":"16","author":"Group","year":"1990","journal-title":"Health Policy"},{"issue":"112","key":"10.1016\/j.drugalcdep.2020.108221_bib0060","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jsat.2020.02.002","article-title":"Economic evaluation in the national drug abuse treatment clinical trials network: past, present, and future","volume":"2020","author":"Jalali","year":"2020","journal-title":"J. Subst. Abuse Treat."},{"key":"10.1016\/j.drugalcdep.2020.108221_bib0065","doi-asserted-by":"crossref","first-page":"130","DOI":"10.3389\/fpsyg.2018.00130","article-title":"Evaluation of analysis approaches for latent class analysis with auxiliary linear growth model","volume":"9","author":"Kamata","year":"2018","journal-title":"Front. Psychol."},{"issue":"4","key":"10.1016\/j.drugalcdep.2020.108221_bib0070","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1080\/10705511.2016.1158655","article-title":"Modeling predictors of latent classes in regression mixture models","volume":"23","author":"Kim","year":"2016","journal-title":"Struct. Equ. Model."},{"key":"10.1016\/j.drugalcdep.2020.108221_bib0075","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.jsat.2016.05.001","article-title":"Characterizing long-term health related quality of life trajectories of individuals with opioid use disorder","volume":"67","author":"Krebs","year":"2016","journal-title":"J. Subst. Abuse Treat."},{"key":"10.1016\/j.drugalcdep.2020.108221_bib0080","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.drugalcdep.2014.05.018","article-title":"A latent class analysis of self-reported clinical indicators of psychosocial stability and adherence among opioid substitution therapy patients: do stable patients receive more unsupervised doses?","volume":"142","author":"Larance","year":"2014","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2020.108221_bib0085","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.cct.2016.08.004","article-title":"NIDA clinical trials network CTN-0051, extended-release naltrexone vs. Buprenorphine for opioid treatment (X:BOT): study design and rationale","volume":"50","author":"Lee","year":"2016","journal-title":"Contemp. Clin. Trials"},{"issue":"10118","key":"10.1016\/j.drugalcdep.2020.108221_bib0090","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(17)32812-X","article-title":"Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial","volume":"391","author":"Lee","year":"2018","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.drugalcdep.2020.108221_bib0095","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0740-5472(92)90062-S","article-title":"The fifth edition of the addiction severity index","volume":"9","author":"McLellan","year":"1992","journal-title":"J. Subst. Abuse Treat."},{"issue":"2","key":"10.1016\/j.drugalcdep.2020.108221_bib0100","doi-asserted-by":"crossref","first-page":"90","DOI":"10.7326\/M18-0227","article-title":"Cost-effectiveness of buprenorphine-naloxone versus extended-release naltrexone to prevent opioid relapse","volume":"170","author":"Murphy","year":"2019","journal-title":"Ann. Intern. Med."},{"issue":"9","key":"10.1016\/j.drugalcdep.2020.108221_bib0105","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s40273-016-0400-5","article-title":"Economic evaluations of opioid use disorder interventions","volume":"34","author":"Murphy","year":"2016","journal-title":"Pharmacoeconomics"},{"issue":"6","key":"10.1016\/j.drugalcdep.2020.108221_bib0110","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1111\/j.1530-0277.2000.tb02070.x","article-title":"Integrating person-centered and variable-centered analyses: growth mixture modeling with latent trajectory classes","volume":"24","author":"Muthen","year":"2000","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.drugalcdep.2020.108221_bib0115","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1146\/annurev.clinpsy.121208.131413","article-title":"Group-based trajectory modeling in clinical research","volume":"6","author":"Nagin","year":"2010","journal-title":"Annu. Rev. Clin. Psychol."},{"key":"10.1016\/j.drugalcdep.2020.108221_bib0120","series-title":"Cost Effectiveness in Health and Medicine","author":"Neumann","year":"2017"},{"issue":"2\u20133","key":"10.1016\/j.drugalcdep.2020.108221_bib0125","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.drugalcdep.2011.04.003","article-title":"Health related quality of life trajectories of patients in opioid substitution treatment","volume":"118","author":"Nosyk","year":"2011","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2020.108221_bib0130","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.drugalcdep.2015.10.009","article-title":"Short term health-related quality of life improvement during opioid agonist treatment","volume":"157","author":"Nosyk","year":"2015","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2020.108221_bib0135","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1080\/10705510701575396","article-title":"Deciding on the number of classes in latent class analysis and growth mixture modeling: a Monte Carlo simulation study","author":"Nylund","year":"2007","journal-title":"Struct. Equ. Model. A Multidiscip. J."},{"key":"10.1016\/j.drugalcdep.2020.108221_bib0140","series-title":"Encylopedia of Health Economics","article-title":"Multiattribute utility instruments and their use","author":"Richardson","year":"2014"},{"key":"10.1016\/j.drugalcdep.2020.108221_bib0145","doi-asserted-by":"crossref","first-page":"107649","DOI":"10.1016\/j.drugalcdep.2019.107649","article-title":"Trajectory classes of opioid use among individuals in a randomized controlled trial comparing extended-release naltrexone and buprenorphine-naloxone","volume":"205","author":"Ruglass","year":"2019","journal-title":"Drug Alcohol Depend."},{"issue":"11","key":"10.1016\/j.drugalcdep.2020.108221_bib0150","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1016\/S0277-9536(99)00045-3","article-title":"Integrating response shift into health-related quality of life research: a theoretical model","volume":"48","author":"Sprangers","year":"1999","journal-title":"Soc. Sci. Med."},{"issue":"4","key":"10.1016\/j.drugalcdep.2020.108221_bib0155","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1080\/10705511.2013.824781","article-title":"Statistical power to detect the correct number of classes in latent profile analysis","volume":"20","author":"Tein","year":"2013","journal-title":"Struct. Equ. Model. A Multidiscip. J."},{"issue":"4","key":"10.1016\/j.drugalcdep.2020.108221_bib0160","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/add.13219","article-title":"Measuring benefits of opioid misuse treatment for economic evaluation: health\u2010related quality of life of opioid\u2010dependent individuals and their spouses as assessed by a sample of the US population","volume":"111","author":"Wittenberg","year":"2016","journal-title":"Addiction"}],"container-title":["Drug and Alcohol Dependence"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871620303860?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871620303860?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T09:05:31Z","timestamp":1759827931000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0376871620303860"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":32,"alternative-id":["S0376871620303860"],"URL":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2020.108221","relation":{},"ISSN":["0376-8716"],"issn-type":[{"value":"0376-8716","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Health-related quality of life and opioid use disorder pharmacotherapy: A secondary analysis of a clinical trial","name":"articletitle","label":"Article Title"},{"value":"Drug and Alcohol Dependence","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2020.108221","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108221"}}